Discovering breakthroughs in fibrosis and neurodegeneration

Our Pipeline

Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.

Our focused approach offers the potential to produce disease-modifying, life-saving therapies.

1 Autotaxin Inhibitor
2 Calpain Inhibitor
3 Idiopathic Pulmonary Fibrosis
4 Systemic Sclerosis – Interstitial Lung Disease